There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TransCode Therapeutics (RNAZ – Research Report), Tarsus Pharmaceuticals (TARS – Research Report) and Roivant Sciences (ROIV – Research Report) with bullish sentiments.
TransCode Therapeutics (RNAZ)
In a report released today, Emily Bodnar from H.C. Wainwright initiated coverage with a Buy rating on TransCode Therapeutics and a price target of $12.00. The company’s shares closed last Wednesday at $2.48, close to its 52-week low of $2.44.
According to TipRanks.com, Bodnar is a 1-star analyst with an average return of
TransCode Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See the top stocks recommended by analysts >>
Tarsus Pharmaceuticals (TARS)
Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals today and set a price target of $40.00. The company’s shares closed last Wednesday at $17.87.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of
Tarsus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $46.83, implying a 174.8% upside from current levels. In a report issued on June 15, Bank of America Securities also maintained a Buy rating on the stock with a $42.00 price target.
Roivant Sciences (ROIV)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences today and set a price target of $18.00. The company’s shares closed last Wednesday at $10.07, close to its 52-week high of $10.83.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $15.43 average price target, representing a 68.1% upside. In a report issued on June 20, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNAZ:
- Transcode Therapeutics announces new data relevant to TTX-MC138
- TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
- TransCode Therapeutics Announces Closing of $7 Million Public Offering
- TransCode Therapeutics Announces Pricing of $7 Million Public Offering
- TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
